Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OLMA 
Olema Pharmaceuticals Inc (OLMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OLMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.71
1 Year Target Price $24.71
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.46% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 316.11M USD | Price to earnings Ratio - | 1Y Target Price 24.71 |
Price to earnings Ratio - | 1Y Target Price 24.71 | ||
Volume (30-day avg) 8 | Beta 2.01 | 52 Weeks Range 2.86 - 16.62 | Updated Date 06/30/2025 |
52 Weeks Range 2.86 - 16.62 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.44% | Return on Equity (TTM) -41.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -74768488 | Price to Sales(TTM) - |
Enterprise Value -74768488 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.33 | Shares Outstanding 68421296 | Shares Floating 43108141 |
Shares Outstanding 68421296 | Shares Floating 43108141 | ||
Percent Insiders 3.32 | Percent Institutions 98.61 |
Analyst Ratings
Rating 3 | Target Price 24.71 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Olema Pharmaceuticals Inc
Company Overview
History and Background
Olema Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for womenu2019s cancers. Founded in 2018, Olema went public in November 2020. The company is dedicated to improving treatment options for patients living with cancer.
Core Business Areas
- Oncology Drug Development: Olema focuses on developing therapies that target signaling pathways associated with tumor growth and resistance mechanisms in breast and other cancers.
Leadership and Structure
Sean P. Bohen, M.D., Ph.D., is the President and Chief Executive Officer. The company has a management team overseeing research and development, clinical operations, and corporate strategy.
Top Products and Market Share
Key Offerings
- OP-1250: OP-1250 is Olema's lead product candidate, an oral Selective Estrogen Receptor Degrader (SERD) with potential best-in-class properties, in clinical development for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Market share information isn't yet applicable since the product is still in clinical trials. Key competitors developing SERDs include Radius Health and Menarini Group.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and rapidly evolving, with significant investment in cancer therapeutics. Development success is driven by high levels of unmet medical need.
Positioning
Olema aims to become a leader in targeted therapies for women's cancers, particularly ER+/HER2- breast cancer. They are focused on addressing limitations of current endocrine therapies and overcoming resistance mechanisms.
Total Addressable Market (TAM)
The TAM for breast cancer therapies is substantial and expected to grow. Olema is positioned to capture a portion of this market with OP-1250 by providing a more effective and convenient treatment option.
Upturn SWOT Analysis
Strengths
- Strong scientific team
- Promising lead product candidate (OP-1250)
- Targeted approach to women's cancers
- Focus on unmet medical needs
Weaknesses
- Reliance on a single lead product candidate
- Clinical trial risks
- Limited commercial infrastructure
- Cash burn rate
Opportunities
- Expansion of OP-1250 to other indications
- Partnerships with larger pharmaceutical companies
- Advancement of pipeline programs
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- AZN (AstraZeneca)
- PFE (Pfizer)
- LLY (Eli Lilly and Company)
Competitive Landscape
Olema's competitive advantage lies in its potentially best-in-class OP-1250. Disadvantages include limited resources compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth primarily relates to research and development activities and financing rounds.
Future Projections: Future growth depends on successful clinical trials and potential commercialization of OP-1250. Analyst estimates vary widely given the inherent uncertainty.
Recent Initiatives: Recent initiatives include advancing OP-1250 through clinical trials and expanding the pipeline.
Summary
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising lead product candidate targeting ER+ breast cancer. Their success hinges on the clinical development and eventual commercialization of OP-1250. A key risk lies in the possibility of clinical trial failures. They need to secure partnerships and effectively manage cash burn to achieve long-term growth and withstand competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Olema Pharmaceuticals Inc. Investor Relations
- SEC Filings (10K, 10Q)
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Olema Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-11-19 | President, CEO & Director Dr. Sean P. Bohen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://olema.com |
Full time employees 101 | Website https://olema.com | ||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.